In a study by Lee et al. (106), MAL expression patterns showed significant reverse correlation with platinum resistance, and the DNA methylation status of the MAL promoter region can be used as a marker for platinum drug sensitivity and as a therapeutic target in ovarian cancer. The gene discussed is MAL; the disease is ovarian carcinoma.